Alaunos Therapeutics Inc (TCRT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) has a cash flow conversion efficiency ratio of -0.256x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-552.00K) by net assets ($2.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alaunos Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Alaunos Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Alaunos Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alaunos Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Betacom S.A.
WAR:BCM
|
0.046x |
|
Gayatri Highways Limited
NSE:GAYAHWS
|
1.168x |
|
Warehouse REIT plc
LSE:WHR
|
0.027x |
|
Munic SA
PA:ALMUN
|
0.114x |
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
-6.792x |
|
Gentrogroup Co. Ltd.
KQ:083660
|
-0.156x |
|
CHINA HEALTH GRP HD-10
F:VNL1
|
N/A |
|
mTouche Technology Bhd
KLSE:0092
|
-0.111x |
Annual Cash Flow Conversion Efficiency for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual cash flow conversion efficiency of Alaunos Therapeutics Inc from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see TCRT market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $2.15 Million | $-2.87 Million | -1.333x | +44.70% |
| 2024-12-31 | $2.06 Million | $-4.97 Million | -2.410x | +49.58% |
| 2023-12-31 | $6.31 Million | $-30.14 Million | -4.779x | -530.33% |
| 2022-12-31 | $38.55 Million | $-29.23 Million | -0.758x | +28.39% |
| 2021-12-31 | $58.06 Million | $-61.47 Million | -1.059x | -130.24% |
| 2020-12-31 | $123.98 Million | $-57.01 Million | -0.460x | -6.94% |
| 2019-12-31 | $95.01 Million | $-40.85 Million | -0.430x | +25.61% |
| 2018-12-31 | $85.56 Million | $-49.46 Million | -0.578x | -202.35% |
| 2017-12-31 | $-96.81 Million | $-54.67 Million | 0.565x | -25.16% |
| 2016-12-31 | $-77.30 Million | $-58.33 Million | 0.755x | +659355.55% |
| 2015-12-31 | $87.37 Million | $-10.00K | 0.000x | +99.99% |
| 2014-12-31 | $33.84 Million | $-36.65 Million | -1.083x | +10.13% |
| 2013-12-31 | $49.38 Million | $-59.51 Million | -1.205x | +25.95% |
| 2012-12-31 | $48.45 Million | $-78.83 Million | -1.627x | -200.04% |
| 2011-12-31 | $71.61 Million | $-38.84 Million | -0.542x | +15.86% |
| 2010-12-31 | $30.55 Million | $-19.69 Million | -0.645x | -47.35% |
| 2009-12-31 | $28.10 Million | $-12.29 Million | -0.437x | +87.47% |
| 2008-12-31 | $6.74 Million | $-23.52 Million | -3.490x | -389.56% |
| 2007-12-31 | $30.37 Million | $-21.65 Million | -0.713x | -31.16% |
| 2006-12-31 | $26.53 Million | $-14.42 Million | -0.544x | +55.42% |
| 2005-12-31 | $7.20 Million | $-8.78 Million | -1.219x | -450.55% |
| 2004-12-31 | $-21.02K | $-7.31K | 0.348x | -4.28% |
| 2003-12-31 | $-25.69K | $-9.33K | 0.363x | -46.49% |
| 2002-12-31 | $-17.33K | $-11.77K | 0.679x | -94.13% |
| 2001-12-31 | $-2.62K | $-30.26K | 11.570x | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops small molecules to treat obesity and other metabolic disorders. The company develops an oral obesity compound that addresses shortcomings of injectable GLP-1 receptor agonists, including preserving lean muscle mass. It also evaluates ALN1001 and related derivatives on lipid deposition and gene expression.… Read more